Tarantula venom may offer muscular dystrophy cure
January 2nd, 2010 - 2:07 pm ICT by ANILondon, Jan 2 (ANI): Scientists at University at Buffalo have discovered a protein in tarantula venom that could offer potential treatment for muscular dystrophy (MD).
The research team led by Dr Fredrick Sachs, professor of physiology and biophysics at the University at Buffalo has identified a peptide, called GsMTx4.
The peptide also has potential as a therapy for several other conditions, such as neuropathic pain and atrial fibrillation, reports First Science.
The researchers have formed a start-up biotech company in Buffalo, called the Rose Pharmaceuticals, and are working to develop the peptide into a potential drug.
During the study, the team tested the effect of GsMTx4 on MD mice extensively and found that the drug increased muscle strength and caused no mortality, morbidity or toxicity.
The therapies for muscular dystrophy are classed as “orphan drugs” by the FDA, allowing a shorter testing period than normal drugs. (ANI)
- Tarantula venom could help treat muscular dystrophy - Dec 31, 2009
- Two new drugs can slash stroke risk - Jan 11, 2011
- Math model to monitor heartbeat health - Feb 19, 2012
- Healthy lifestyles could halve cases of atrial fibrillation - Mar 29, 2011
- Are erratic heartbeats tied to unexplained strokes? - Feb 03, 2012
- Measuring oxidative stress may help predict atrial fibrillation risk - Apr 05, 2011
- Manipulating muscle stem cells could treat muscular dystrophy - Oct 10, 2010
- Sea snail venom offers potent pain relief - Jun 16, 2010
- Human protein slows muscle damage in muscular dystrophy mice - Dec 28, 2010
- Reports of problems with blood-thinner wrong: study - Aug 30, 2010
- Yoga reduces irregular heartbeat and anxiety - Apr 04, 2011
- First non-surgical procedure to prevent major cause for heart-related stroke performed in US - Aug 22, 2009
- Moderate-to-heavy alcohol intake may increase risk of abnormal heart rhythm - Feb 15, 2011
- Arthritis invites higher risk of heart attacks - Mar 09, 2012
- London hospital to do Europe's first embryonic stem cell trial - Sep 24, 2011
Tags: biophysics, biotech company, fibrillation, first science, fredrick, london jan, mice, mortality morbidity, muscle strength, muscular dystrophy, orphan drugs, peptide, pharmaceuticals, physiology, protein, sachs, tarantula, toxicity, university at buffalo, venom